- CEO
- Zong Bin Yu
- Full Time Employees
- 10,864
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 1 Taiji Road Chongqing CH China 401123
- IPO Date
- Nov 18, 1997
- Business
- Chongqing Taiji Industry (Group) Co., Ltd. (600129.SS) develops, manufactures, and sells traditional Chinese medicines and modern pharmaceuticals in China and select international markets. The company operates through Pharmaceutical Industry, Pharmaceutical Commercial, Chinese Herbal Medicine Resources, Big Health, and Service Industry and Others segments; it offers digestive system and metabolic drugs such as trimetazidine and Bushenyishou capsules, respiratory system drugs including acute bronchitis syrup and Huoxiangzhengqi oral liquid, cardiovascular and cerebrovascular drugs like Tongtian oral liquid and Salvia oral solution, anti-infective drugs, nervous system drugs, anti-tumor and immunomodulatory drugs such as paclitaxel and Xiaojin tablets, health products, and chemical medicines including Taiji Ginseng Extract and Taiji Bile Powder; it also engages in pharmaceutical distribution and retail, medicinal material planting research and development, accommodation, warehousing, catering, retail, agriculture, wholesale, and aquaculture activities. Founded in 1972 and headquartered at No. 18 Hengshan East Road, Yubei District, Chongqing, China, the company maintains over 10 manufacturing facilities across China adhering to GMP standards, employs approximately 11,971 people, and generates the majority of its revenue from Southwest China with additional sales in East, Northern, South, Central, North-West, and North-East China as well as overseas markets. In late 2024, Chongqing Taiji Industry announces plans to acquire 100% equity in Taiji Group Chongqing Tongjun Pavilion Pharmaceutical Factory for 147.3 million yuan with a 320 million yuan capital increase and full equity in Taiji Group Chongqing Traditional Chinese Medicine Factory No. 2 for 29.8 million yuan with a 185 million yuan capital increase to expand its production capabilities; the board authorizes a share buyback plan in July 2025, and the company reports earnings for Q1 2025 and full-year 2024 while maintaining strategic financial services agreements with Sinopharm Group Finance Co., Ltd.